CST, 26941S, Human NRG1-beta1 Recombinant Protein

Storage
Human NRG1-β1 Recombinant Protein is supplied as lyophilized material that is very stable at -20°C. It is recommended to reconstitute with sterile water at a concentration of 0.1 mg/ml which can be further diluted in aqueous solutions as needed. Addition of a carrier protein (0.1% HSA or BSA) is recommended for long-term storage. Once in solution, store at 4°C and use within 1 month, or store at -20ºC to -80ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles if storing reconstituted material at -20ºC to -80ºC.
Source / Purification
Recombinant human NRG1-β1 was expressed in and is supplied in a lyophilized form.
Background
Neuregulin 1 (NRG1), a member of the EGF family, is involved in heart, mammary, and nervous system development (1). NRG1 is expressed by mammary epithelial, vascular endothelial, and neuronal cells (2,3). At least 15 NRG1 splice variants are known (1). These variants differ in EGF domains (α or β variants), amino-terminal splicing sites, and in the incorporation of exons encoding integral membrane regions (1). NRG1 can induce or inhibit the proliferation of cells derived from breast cancer. The differences in effects of NRG1 appear to depend on splice variation and interaction with receptor(s) (2). NRG1 binds to ErbB3/HER3 or ErbB4/HER4. Binding induces dimerization with ErbB2/HER2. The Akt, Erk1/2, and Erk5 pathways have been shown to participate in NRG1 activated signaling (4,5). NRG1 appears to have roles in schizophrenia and breast cancer (1,4,6).